MitoKor, Inc. provided discovery and diagnostic development of mitochondrial medicine. It was a biotechnology company focused on the research and development of drugs for the treatment of major diseases and conditions associated with mitochondrial dysfunction. The company was headquartered in San Diego, CA

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

NuSirt Sciences is a biotechnology company focused on developing products targeting metabolic diseases associated with over-nutrition such as obesity, diabetes, and inflammatory stress. The company has developed a breakthrough technology platform that combines natural compounds with various pharmaceutical agents. NuSirts first product, NS-0100, uses NuSirts platform technology to combine the natural product leucine with a very low dose of metformin for the treatment of type II diabetes. Although, metformin is the gold standard in the treatment of early-type II diabetes many patients can not tolerate the adverse gastrointestinal side effects metformin can cause in some patients. The company is currently testing varying doses of NS-0100 in Phase 2 clinical study to find the most efficacious dose of this new combination. If NuSirts clinical trials are successful NS-0100 may offer patients a viable alternative to metformin. NuSirt has filed eleven patent applications (two of which have been issued) and completed four clinical and numerous pre-clinical studies based on the patented technologies.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Edison is a world leader in the discovery and development of redox drugs. The company has obtained orphan designation in both the United States and Europe for its first drug candidate, EPI-743 . Vincerinone is now in phase 2 clinical development. It is being evaluated in multiple clinical indications where defects in the mitochondrial proteins and redox control have been well characterized.

BASF AB supplies raw materials to paper, chemicals, and construction industries. Its products include construction chemical, crop protection products, dispersions and pigments, plastics, polyurethane systems and coating products. The company was founded in 1953 and is headquartered in Göteborg, Sweden.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Graffinity Pharmaceuticals AG specializes in chemical genomics pharmaceutical products. Through its fragment based chemical genomics platform, it provides novel small molecules for drug discovery and chemical genomics approaches. The company was founded in 1998 and is headquartered in Heidelberg, Germany.

Khondrion BV is a company headquartered in Nijmegen, the Netherlands, that manufactures and markets pharmaceutical products. It was founded in 2012 by Jan Smeitink, who has been the CEO since that date.\nThe company says this about itself: Khondrion is a clinical stage biopharmaceutical company developing therapies for patients with inherited mitochondrial diseases. Based on proprietary science and a deep biological understanding of mitochondrial dysfunction, the company is advancing its lead drug candidate sonlicromanol. Sonlicromanol is a first-in-class, oral small molecule targeting key underlying mechanisms of mitochondrial disease based on its uniquely differentiated triple mode of action: reductive distress modulation to help restore the cell?s metabolism, oxidative distress modulation preventing ferroptotic cell death, and selective mPGES-1 inhibition resulting in anti-inflammatory effects.

Wellstat Therapeutics Corporation is a privately-held biopharmaceutical company located in Gaithersburg, Maryland. Dedicated to the discovery, development and commercialization of innovative therapeutics that expand the frontiers of medicine, Wellstat Therapeutics Corporation is committed to improving the lives of patients with chronic and life-threatening diseases.\nWellstat Therapeutics's focus is in the following fields:\nOncology\nMetabolic Diseases\nNeurodegenerative Diseases\nNeurometabolic Diseases\nWellstat Therapeutics is developing an extensive and diverse pipeline of novel small molecule therapeutic agents. The Company owns a broad patent portfolio covering this technology and is constantly expanding its intellectual property estate. Wellstat Therapeutics' pipeline spans the stages of development from discovery through Phase III clinical trials.\nWellstat Therapeutics was founded in 1985. The Company has a highly talented management team with significant experience in drug discovery, development, and commercialization. Samuel J. Wohlstadter, a company founder and the Chief Executive Officer was also a founder of Amgen Inc., Applied Biosystems (currently a division of Applera Corporation), IGEN International Inc. (currently a subsidiary of Roche), BioVeris Corporation (currently a subsidiary of Roche), and Hyperion Catalysis International, Inc.\nWellstat Therapeutics employs dedicated scientists, business professionals and support personnel at its state-of-the-art facilities in Gaithersburg, Maryland. Wellstat Therapeutics is part of the Wellstat Group of Companies, one of the largest and leading bioscience employers in the Baltimore-Washington Metropolitan Area. The Wellstat Group of Companies has expertise in all stages of discovery research and development, including:\nChemistry\nCell and Molecular Biology\nDisease Models\nTranslational Biology\nClinical Research and Development\nProject Management\nRegulatory Quality Assurance and Control\nManufacturing\nLegal and Financial

Gevo, Inc. is a renewable chemicals and next generation biofuels company, which focuses on the development and commercialization of renewable alternatives to petroleum-based products. It operates through the following segments: Gevo and Gevo Development and Agri-Energy. The Gevo segment focuses on the research and development activities related to the future production of isobutanol, including the development of the firm's proprietary biocatalysts, the production and sale of renewable jet and other fuels, the retrofit process, and the next generation of chemicals and biofuels that will be based on the company's isobutanol technology. The Gevo Development and Agri-Energy segment is currently responsible for the operation of its agri-energy facility and the production of ethanol, isobutanol, and related products. The company was founded by Christopher Michael Ryan, Matthew W. Peters, Peter Meinhold, and Frances Hamilton Arnold on June 9, 2005 and is headquartered in Englewood, CO.

Established in 1945, Amorepacific is Korea’s No.1 beauty company and a blue-chip corporation. Amorepacific owns nearly 30 well-known brands and has been developing rapidly worldwide. Amorepacific pays great attention to product research and development through research centers located in Korea, France, Japan and Shanghai, to develop premium and high quality skincare and cosmetics products. The Group chose Hong Kong as a strategic bridgehead for the expansion of its presence across the Greater China region and the rest of the world. Two flagship brands - LANEIGE and Sulwhasoo, were introduced in Hong Kong in 2002 and 2004 respectively. The eponymous luxury brand – AMOREPACIFIC, was introduced in Hong Kong in 2014. In 2015, ETUDE HOUSE, a playful cosmetics brand, made its debut in the territory. In 2018, the Company set foot in the personal care product market, introducing the Group’s legendary hair care brand ‘Ryo’ into Hong Kong.

Ibis Biosciences, Inc. develops, manufactures, and markets products for the identification and characterization of infectious agents. It offers The Ibis T5000 Biosensor System, a hardware platform for the identification of biological organisms, including bacteria, viruses, fungi, and protozoa, as well as provides information about drug resistance, virulence, and strain type. The company also provides assay kits and panels for strain genotyping and characterization. In addition, it supplies plates, buffers, and related consumables for PCR and various reagents for desalting. Further, the company offers assay services, such as human forensics and mitochondrial DNA assay services; bacterial and viral detection and profiling; and bacterial and viral surveillance services. Ibis Biosciences provides its products for use in applications, such as clinical research, healthcare-associated infection, surveillance, and forensics. The company was incorporated in 2006 and is based in Carlsbad, California. As of January 6, 2009, Ibis Biosciences, Inc. operates as a subsidiary of Abbott Molecular Inc.

Teijin Ltd. engages in the management of its group companies that are involved in the environment and energy, safety and protection, information and electronics, transportation, and healthcare businesses. It operates through the following segments: Materials, Healthcare, and Others. The Materials segment handles the manufacture and sale of polyester, aramid, and carbon fiber products as well as plastic and resin products from polycarbonate resin and polyester film. The Healthcare segment deals with the manufacture and sale of pharmaceuticals and home medical equipment. It also provides home healthcare services. The Others segment offers information technology services. The company was founded by Seita Kumura, Itsuzo Hata, and Naokichi Kaneko on June 17, 1918 and is headquartered in Osaka, Japan.

Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts is a teaching hospital of Harvard Medical School. It was formed out of the 1996 merger of Beth Israel Hospital (founded in 1916) and New England Deaconess Hospital (founded in 1896). Among independent teaching hospitals, Beth Israel Deaconess Medical Center consistently ranks in the top three recipients of biomedical research funding from the National Institutes of Health. Research funding totals nearly $200 million annually. BIDMC researchers run more than 850 active sponsored projects and 200 clinical trials. The Harvard-Thorndike General Clinical Research Center, the oldest clinical research laboratory in the United States, has been located on this site since 1973.